221 related articles for article (PubMed ID: 36226800)
1. Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform.
Visone R; Lozano-Juan F; Marzorati S; Rivolta MW; Pesenti E; Redaelli A; Sassi R; Rasponi M; Occhetta P
Toxicol Sci; 2023 Jan; 191(1):47-60. PubMed ID: 36226800
[TBL] [Abstract][Full Text] [Related]
2. Assessment of extracellular field potential and Ca
Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
[TBL] [Abstract][Full Text] [Related]
3. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
[TBL] [Abstract][Full Text] [Related]
4. An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.
Clark AP; Wei S; Kalola D; Krogh-Madsen T; Christini DJ
Br J Pharmacol; 2022 Oct; 179(20):4829-4843. PubMed ID: 35781252
[TBL] [Abstract][Full Text] [Related]
5. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
6. Frequency-Dependent Multi-Well Cardiotoxicity Screening Enabled by Optogenetic Stimulation.
Rehnelt S; Malan D; Juhasz K; Wolters B; Doerr L; Beckler M; Kettenhofen R; Bohlen H; Bruegmann T; Sasse P
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211031
[TBL] [Abstract][Full Text] [Related]
7. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
9. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
[TBL] [Abstract][Full Text] [Related]
11. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
12. A 3-D human model of complex cardiac arrhythmias.
Williams K; Liang T; Massé S; Khan S; Hatkar R; Keller G; Nanthakumar K; Nunes SS
Acta Biomater; 2021 Sep; 132():149-161. PubMed ID: 33713861
[TBL] [Abstract][Full Text] [Related]
13. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
[TBL] [Abstract][Full Text] [Related]
15. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.
Li M; Kanda Y; Ashihara T; Sasano T; Nakai Y; Kodama M; Hayashi E; Sekino Y; Furukawa T; Kurokawa J
J Pharmacol Sci; 2017 Jun; 134(2):75-85. PubMed ID: 28615142
[TBL] [Abstract][Full Text] [Related]
17. A predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues.
Kofron CM; Kim TY; Munarin F; Soepriatna AH; Kant RJ; Mende U; Choi BR; Coulombe KLK
Sci Rep; 2021 May; 11(1):10228. PubMed ID: 33986332
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
[TBL] [Abstract][Full Text] [Related]
19. Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Higa A; Hoshi H; Yanagisawa Y; Ito E; Morisawa G; Imai JI; Watanabe S; Takagi M
J Toxicol Sci; 2017; 42(6):755-761. PubMed ID: 29142174
[TBL] [Abstract][Full Text] [Related]
20. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
De Clerck F; Van de Water A; D'Aubioul J; Lu HR; van Rossem K; Hermans A; Van Ammel K
Fundam Clin Pharmacol; 2002 Apr; 16(2):125-40. PubMed ID: 12031065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
